Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

RON (recepteur d'origine nantais) and MET (hepatocyte growth factor receptor) are tyrosine kinase receptors. Various cancers have aberrant RON and MET expression and activation, which contribute to cancer cell proliferation, invasiveness, and metastasis. Here, we explored RON and MET expression...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Chen-Yu Hu, Xiang-Ming Xu, Bo Hong, Zhi-Gang Wu, Yun Qian, Tian-Hao Weng, Yi-Zhi Liu, Tao-Ming Tang, Ming-Hai Wang, Hang-Ping Yao
Формат: Artigo
Язык:Inglês
Опубликовано: Frontiers Media S.A. 2019-12-01
Серии:Frontiers in Oncology
Предметы:
pancreatic cancer
tyrosine kinase inhibitors
RON receptor tyrosine kinase
MET receptor tyrosine kinase
prognosis biomarker
therapeutic target
Online-ссылка:https://www.frontiersin.org/article/10.3389/fonc.2019.01377/full
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы